Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

Journal of Clinical Oncology

Volumn 17, Issue 10, 1999, Pages 3173-3181

  Bajorin, Dean F ^a   Dodd, Paul M ^a   Mazumdar, Madhu ^a   Fazzari, Melissa ^a   McCaffrey, John A ^a   Scher, Howard I ^a   Herr, Harry ^a   Higgins, Geralyn ^a   Boyle, Mary G ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

EID: 0032887956     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.10.3173     Document Type: Article

References (25)

1. Sternberg CN, Yagoda A, Scher HI, et al: Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Cancer 64:2448-2458, 1989
2. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 10:1066-1073, 1992
3. Logothetis CJ, Dexeus FH, Finn L, et al: A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8:1050-1055, 1990
4. Saxman SB, Propert KJ, Einhorn LH, et al: Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 15:2564-2569, 1997
5. Roth BJ, Dreicer R, Einhorn LH, et al: Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12-2264-2270, 1994
6. Stadler WM, Kuzel T, Roth B, et al: Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15:3394-3398, 1997
7. Moore MJ, Tannock IF, Ernst DS, et al: Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15:3441-3445, 1997
8. Witte RS, Elson P, Bono B, et al: Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 15:589-593, 1997
9. McCaffrey JA, Hilton S, Mazumdar M, et al: Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 15:1853-1857, 1997
10. Vaughn DJ, Malkowicz SB, Zoltick B, et al: Paclitaxel plus/ carboplatin in advanced carcinoma of the urothelium: An active and tolerable outpatient regimen. J Clin Oncol 16:255-260, 1998
11. Redman BG, Smith DC, Flaherty L, et al: Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol 16:1844-1848, 1998
12. Droz JP, Mottet N, Prapotrich D, et al: Phase II study of Taxol (paclitaxel) and carboplatin in patients with advanced transitional-cell carcinoma of the urothelium: Preliminary results. Proc Am Soc Clin Oncol 17:316a, 1998 (abstr 1219)
13. Moore MJ, Tannock I, Winquist E, et al: Gemcitabine (G) + cisplatin (C): An active regimen in advanced transitional cell carcinoma (TCC). Proc Am Soc Clin Oncol 17:320a, 1998 (abstr 1234)
14. Kaufman D, Stadler W, Carducci M, et al: Gemcitabine (GEM) plus cisplatin (CDDP) in metastatic transitional cell carcinoma (TCC): Final results of a phase II study. Proc Am Soc Clin Oncol 17:320a, 1998 (abstr 1235)
15. Dreicer R, Roth B, Lipsitz S, et al: E2895 cisplatin and paclitaxel in advanced carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group (ECOG). Proc Am Soc Clin Oncol 17:320a, 1998 (abstr 1233)
16. Bellmunt J, Carles J, Climent MA, et al: Phase I trial of paclitaxel, cisplatin, and gemcitabine (TCG) in patients (pts) with advanced transitional cell carcinoma (TCC) of the urothelium. Proc Am Soc Clin Oncol 17, 1998 (abstr 1236)
17. Meyers FJ, Edelman MJ, Houston J, et al: Phase I/II trial of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma. Proc Am Soc Clin Oncol 17:317a, 1998 (abstr 1222)
18. Bajorin DF, McCaffrey JA, Hilton S, et al: Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: A phase II trial. J Clin Oncol 16:2722-2727, 1998
19. Geller NL, Sternberg CN, Penenberg D, et al: Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer 67:1525-1531, 1991
20. Gabrilove JL, Jakubowski A, Scher H, et al: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414-1422, 1988
21. Dodd PM, McCaffrey JA, Mazumdar M, et al: Phase II trial of intermediate-dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. Cancer 85:1145-1150, 1999
22. Seidman AD, Scher HI, Gabrilove JL, et al: Dose-intensification of M-VAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 11:408-414, 1993
23. McCaffrey JA, Hilton S, Mazumdar M, et al: Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional cell carcinoma. J Clin Oncol 15:2449-2455, 1997
24. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
25. Chen CH, George SL: The bootstrap and identification of prognostic factors vis Cox's proportional hazards regression model. Stat Med 4:39-46, 1985